Manufacturer: Cipla, India
Pharmaceutical name: Abacavir
Pack: 30 pills (300 mg)
Abamune is utilized as part of a combination therapy of anti-HIV medications to treat HIV-1. Each tablet contains Abacavir equivalent to 300 mg of Abacavir. To prevent the advancement of HIV-1 to AIDS, Abamune should be taken with additional antiretrovirals.
The suggested oral dosage for adults with HIV-1 is one 300 mg tablet of Abamune taken twice a day, together with other antiretroviral drugs. Unlike many anti-HIV medications, there is no need to modify the dosage for individuals with kidney issues. Children aged between three months and 16 years can take 8 mg/kg twice daily. Those with mild liver impairment, as indicated by a Child-Pugh score of 5 to 6, should limit their intake to 200 mg twice daily. Abamune may be taken regardless of food consumption.
Patients who are hypersensitive to Abacavir and those with moderate to severe liver impairment should avoid taking Abamune.
Mild side effects linked to Abamune include: cough, gastritis, slight increases in blood glucose levels, headache, nausea, stomach pain, diarrhea, vomiting, and anemia.
Severe side effects reported in patients using Abamune consist of: thrombocytopenia, neutropenia, abnormal liver function tests, elevated CPK levels, pharyngitis, pancreatitis, toxic epidermal necrolysis, increased gamma glutamyl transferase, Stevens-Johnson syndrome, myocardial infarction, body fat redistribution, sleep disturbances, dyspnea, lactic acidosis, and hepatomegaly with steatosis.
Abamune may lead to other side effects. Notify your doctor immediately if you notice any health changes after beginning Abamune.
If it cannot be ruled out that an individual is hypersensitive to Abacavir, Abamune should be ceased permanently. Those taking Abamune who are at risk for liver disease may have a higher chance of experiencing hepatotoxicity and lactic acidosis. Increased caution is advised when prescribing Abamune to older patients. There is a potential for cross-resistance when Abamune is taken alongside other NRTIs.
Abamune has not been found to impact cytochrome P450 isoforms, making it unlikely to interact with drugs processed through these metabolic pathways.
No specific antidote for Abamune has been identified, and it remains uncertain whether Abamune can be eliminated via dialysis. Do not exceed the prescribed amount of Abamune.